Featured

Status

Health Topics

Any Category
Diseases
Neoplasms
Clear Filters

Search Clinical Trials

137 Results
Completed
Donor-Derived Humoral Immunity, Hematopoietic Stem Cell Transplantation, TAR
To participate in this study, patients will need to have given informed consent to have a bone marrow transplant. Before receiving the tetanus vaccine, we would like to test the …
Baylor Role: Collaborator
Terminated
T-Reg Cell Kinetics, Stem Cell Transplant, REGALE
To participate in this transplant, the patient will need to have a central line. Before the transplant we will test the blood for viruses which can cause problems after the …
Baylor Role: Lead Sponsor
Terminated
T-Regulatory Cell Kinetics, Stem Cell Transplantation, REGKINE
Before the transplant we will test the patients blood for viruses which can cause problems after the transplant. These viruses include Hepatitis B, (which causes liver damage), cytomegalovirus, (which causes …
Baylor Role: Lead Sponsor
Completed
LMP1- and LMP2-Specific CTLs to Patients With EBV-Positive NPC (NATELLA)
Patients have an EBV-positive cancer. We had gotten permission to take blood from patients in the past, which was used to grow T cells in the laboratory. We first grew …
Baylor Role: Lead Sponsor
Withdrawn
Study of LMP1- and LMP2- Specific Cytotoxic T-Lymphocytes (CTL)
While patients with nasopharyngeal carcinoma (NPC) may be cured by chemotherapy and radiotherapy, the outlook for patients who are resistant to this treatment or who relapse is poor. Almost all …
Baylor Role: Lead Sponsor
Completed
Low Dose IL-2, Hematopoietic Stem Cell Transplantation, IL2 for GVHD
Participation in this protocol will last about 1 year. To participate in this study, the patient will need to have undergone a stem cell transplant. Before the treatment starts, investigators …
Baylor Role: Lead Sponsor
Terminated
Reduced Intensity Preparative Regimen Followed by Stem Cell Transplant (FAB)
Allogeneic stem cell transplantation with high-dose chemotherapy affords a better chance of cure of malignant and non-malignant hematological diseases compared to autologous transplantation, because of the lack of stem cell …
Baylor Role: Lead Sponsor
Completed
Protracted Etoposide During Induction Therapy for High Risk Neuroblastoma
Induction Phase Overview The induction phase is approximately 15 weeks long. Chemotherapy is generally given every 3 weeks, each 3 week block is called a "cycle". During these 15 weeks …
Baylor Role: Lead Sponsor
Completed
Tamoxifen for Progressive Transitional Cell Carcinoma Following Previous Chemotherapy Treatment
The major objective of this two-stage phase II study is to determine whether tamoxifen is deserving of further study in metastatic bladder cancer. Tamoxifen is expected to function as a …
Completed
Treatment of B-Chronic Lymphocytic Leukemia (B-CLL) With Autologous CD40 Ligand and IL-2-Expressing Tumor Cells
Previously, some of the cancer cells taken from the patients body were separated in the laboratory and a specially produced human virus (adenovirus) that carries the IL-2 gene was put …
Baylor Role: Lead Sponsor